Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating
patients with advanced esophageal cancer or stomach cancer. Erlotinib hydrochloride may stop
the growth of cancer by blocking the enzymes necessary for tumor cell growth.